Purple Biotech has released more promising interim findings from its randomized Phase 2 study on pancreatic cancer with CM24. These results provide insights into a potential biomarker that could predict an improvement in overall survival.
Fresh information indicates that having lower baseline serum myeloperoxidase (MPO) levels may be linked to a higher likelihood of improved overall survival in patients receiving a combination treatment of CM24, nivolumab, Nal-IRI, 5FU, and LV.
